(Q34221582)

31 July 2017

Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations (English)

1 reference

31 July 2017

0 references

Donald R VanDevanter

1

1 reference

31 July 2017

Mary A O'Riordan

series ordinal

2

1 reference

31 July 2017

Jeffrey L Blumer

series ordinal

3

1 reference

31 July 2017

Michael W Konstan

series ordinal

4

1 reference

31 July 2017

6 October 2010

1 reference

31 July 2017

1 reference

31 July 2017

11

1 reference

31 July 2017

137

1 reference

https://scigraph.springernature.com/pub.10.1186/1465-9921-11-137

31 July 2017

0 references

cites work

Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2959026

Healthcare expenditures for privately insured people with cystic fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2959026

Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2959026

Duration of intravenous antibiotic therapy in people with cystic fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2959026

Cystic fibrosis pulmonary exacerbations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2959026

Management of pulmonary disease in patients with cystic fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2959026

The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2959026

Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2959026

Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone

28 October 2018

1 reference

12 December 2020

Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis

1 reference

12 December 2020

Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy

1 reference

12 December 2020

Pulmonary exacerbations in cystic fibrosis

1 reference

12 December 2020

Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis

1 reference

12 December 2020

Identifiers

DOI

10.1186/1465-9921-11-137

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference

31 July 2017

1 reference